Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Island Pharmaceuticals Ltd ( (AU:ILA) ) is now available.
Island Pharmaceuticals Limited has announced a proposed placement of up to 25,714,285 new fully paid ordinary shares, with an expected issue date of 16 February 2026. The equity raising, to be quoted on the ASX under the company’s existing code ILA, is intended to provide additional capital for the business, underscoring the company’s continued reliance on public market funding to support its pharmaceutical development pipeline and ongoing corporate needs, with potential dilution for existing shareholders depending on final pricing and allocation.
The most recent analyst rating on (AU:ILA) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Island Pharmaceuticals Ltd stock, see the AU:ILA Stock Forecast page.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited is an Australian-listed pharmaceutical company (ASX: ILA) operating in the healthcare and life sciences sector, focused on the development and commercialisation of drug candidates. The company accesses capital markets via the ASX to fund its operations, research and development programs, and broader corporate activities.
Average Trading Volume: 556,089
Technical Sentiment Signal: Buy
Current Market Cap: A$104.9M
Learn more about ILA stock on TipRanks’ Stock Analysis page.